S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

$13.28
+0.09 (+0.68%)
(As of 03/28/2024 ET)
Today's Range
$12.96
$13.63
50-Day Range
$10.81
$17.96
52-Week Range
$8.22
$21.42
Volume
647,590 shs
Average Volume
1.08 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.40

Verve Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
159.0% Upside
$34.40 Price Target
Short Interest
Bearish
25.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.20mentions of Verve Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

691st out of 938 stocks

Pharmaceutical Preparations Industry

314th out of 423 stocks

VERV stock logo

About Verve Therapeutics Stock (NASDAQ:VERV)

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Stock Price History

VERV Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Verve Therapeutics: Q4 Earnings Insights
Verve Therapeutics Shares Gain 16% On 4Q Revenue Beat
Beam Therapeutics, Inc.
Verve Therapeutics co-founder named GV’s new GP
Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Verve Therapeutics Inc (VERV)
3 Stocks to Buy in the Booming Field of Gene Editing
See More Headlines
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
255
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.40
High Stock Price Target
$55.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+159.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-200,070,000.00
Net Margins
-1,701.70%
Pretax Margin
-1,699.21%

Debt

Sales & Book Value

Annual Sales
$11.76 million
Book Value
$7.31 per share

Miscellaneous

Free Float
65,725,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
1.76
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Burt A. Adelman M.D. (Age 72)
    Co-Founder & Independent Chairman of the Board
    Comp: $87.55k
  • Dr. Sekar Kathiresan M.D. (Age 52)
    Co-Founder, CEO & Director
    Comp: $899.55k
  • Mr. Andrew D. Ashe J.D.Mr. Andrew D. Ashe J.D. (Age 57)
    President, COO & General Counsel
    Comp: $703.85k
  • Dr. Andrew Bellinger M.D. (Age 45)
    Ph.D., Chief Scientific Officer
    Comp: $703.85k
  • Dr. Kiran Musunuru M.D.
    M.P.H., Ph.D., Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Anthony Philippakis M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. Barry S. Ticho FACC (Age 63)
    M.D., Ph.D., Co-Founder
  • Mr. Issi Rozen M.B.A.
    Co-Founder & Strategic Advisor
  • Ms. Allison Dorval (Age 48)
    CFO & Principal Accounting Officer
    Comp: $260.93k

VERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings
or view top-rated stocks.

What is Verve Therapeutics' stock price target for 2024?

7 analysts have issued 12 month price targets for Verve Therapeutics' stock. Their VERV share price targets range from $22.00 to $55.00. On average, they predict the company's stock price to reach $34.40 in the next year. This suggests a possible upside of 159.0% from the stock's current price.
View analysts price targets for VERV
or view top-rated stocks among Wall Street analysts.

How have VERV shares performed in 2024?

Verve Therapeutics' stock was trading at $13.94 at the start of the year. Since then, VERV shares have decreased by 4.7% and is now trading at $13.28.
View the best growth stocks for 2024 here
.

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VERV earnings forecast
.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.14. The company had revenue of $5.14 million for the quarter, compared to analyst estimates of $3.95 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative trailing twelve-month return on equity of 39.33%.

When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.02%), Vanguard Group Inc. (8.58%), Vanguard Group Inc. (6.54%), Federated Hermes Inc. (6.24%), Sumitomo Mitsui Trust Holdings Inc. (3.76%) and Nikko Asset Management Americas Inc. (3.76%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends
.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERV) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners